Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Phathom Pharmaceuticals

2 Growth Stocks to Buy Now With 367% to 410% Upside

Strong, innovative pipelines make these two biotech firms smart buys now.

Barchart · Mar 17, 2025

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

Barchart · Feb 24, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · Aug 9, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · Aug 2, 2022

FDA Accepts Review Of Phathom Pharmaceuticals' NDA For Vonoprazan

The Food and Drug Administration (FDA) has accepted for review Phathom Pharmaceuticals’ (NASDAQ: PHAT) New Drug Application (NDA) of its lead drug candidate Vonoprazan for the healing of all grades of erosive esophagitis (EE).

Benzinga · May 25, 2022

Phathom Pharmaceuticals: Q1 Earnings Insights

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022

Coverage From

Organisations

Rhythm Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.